Beryl Capital Management’s Cidara Therapeutics CDTX Stock Holding History

Beryl Capital Management’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-522,138	Closed	-$115M	–	10
2025 Q4	$115M	Buy	+522,138	New	+$84.4M	11.69%	4

Beryl Capital Management's CDTX Position: Q1 2026 in Review

Beryl Capital Management sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 522,138 shares — an estimated $115M sold.

Beryl Capital Management first reported a position in CDTX in Q4 2025 and held it in 1 quarter. The position peaked at $115M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Beryl Capital Management reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Beryl Capital Management sold 522,138 Cidara Therapeutics shares in Q1 2026, an estimated $115M.
Beryl Capital Management first reported a position in Cidara Therapeutics in Q4 2025 and held it in 1 quarter.
Beryl Capital Management's Cidara Therapeutics position peaked at $115M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Beryl Capital Management's 13F filing for Q1 2026, filed 15 May 2026.